Xconomy .com

The battle for control is heating up.

And also commits to making GameHouse social.

One bearish view on Google's new search solution.

The biotech powerhouse has had a tough stretch of late, and now it says it must lay off some of its workforce.

The company has struggled for years but got some good news in a recent study.

And in the toughest patients to treat, too.

The M&A market continues to pick up steam.

Adding a social networking interface, on top of all of iTunes' other functions, is like grafting another limb to the forehead of an octopus. It's just too much.

Who's inching ahead?

Obesity treatments are still a lucrative market.

Genzyme would be a prize for several major drug companies in need of new revenue streams.

Does Microsoft have its hand in enough cookie jars?

In the race to cheaper gene sequencing.

The right time for Google.

This new cleantech player is raising money.

Study results are positive.

Affymax takes on Amgen with its anemia drug.

Kaleetan tries to improve upon Dendreon's breakthrough cancer drug.

Dump your business cards and go digital.

The remains of Lilly's partnership with Vertex Pharmaceuticals.